Program
dapagliflozin
Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.
Drug pageDapagliflozin: every studyMany companies study it; this page follows only the 131 they lead. All 485 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 10910 open or running | phase 4since Jun 2, 2014 | Sep 9, 2005 | Dec 10, 2026phase 2 · NCT07222917 |
| LG Chem | 60 open or running | phase 3since Feb 2, 2020 | May 24, 2018 | none ahead |
| Boryung Pharmaceuticalits history only | 32 open or running | phase 1since May 26, 2022 | May 26, 2022 | none ahead |
| Dong-A STits history only | 20 open or running | phase 3since Apr 20, 2020 | Dec 5, 2018 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 20 open or running | phase 1since Apr 30, 2021 | Apr 30, 2021 | none ahead |
| Autotelicbioits history only | 10 open or running | phase 1since Apr 20, 2021 | Apr 20, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Nov 12, 2020 | Nov 12, 2020 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | no phasesince Nov 7, 2023 | Nov 7, 2023 | none ahead |
| Dong Wha Pharmaceuticalits history only | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| George Clinical Ptyits history only | 10 open or running | phase 4since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Jul 22, 2018 | Jul 22, 2018 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chairits history only | 11 open or running | phase 3since Jun 16, 2025 | Jun 16, 2025 | none ahead |
| Novartisits history only | 10 open or running | phase 2since May 21, 2021 | May 21, 2021 | none ahead |
| THPharmits history only | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
- Named in AstraZeneca’s own pipeline as
zibotentan/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea, Parexel, Ground Zero Pharmaceuticals, PT Equilab International, Bristol-Myers Squibb, Q2 Solutions, PRA Health Sciences, Covance and Antaros Medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LG Chem only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 24, 2018First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT03565458 · 48 enrolled · Korea, Republic of
- Feb 2, 2020Phase 3 study in Diabetes Mellitus, Type 2NCT04255238 · 468 enrolled
- Jul 29, 2020Phase 1 study in T2DMNCT04544319 · 44 enrolled
- Nov 24, 2025Phase 1 study in Fed ConditionsNCT07333742 · 50 enrolled · South Korea
- Jan 23, 2026Phase 1 study in Healthy VolunteersNCT07399470 · 58 enrolled · South Korea
- Feb 2, 2026Phase 1 study in FastingNCT07396844 · 28 enrolled · Thailand
TargetBeta
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
All 6 LG Chem leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07396844Fasting · Thailand | 1 | Completed | Jun 26, 2026 | 28 |
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | Feb 6, 2026 | 58 |
| NCT07333742Fed Conditions · South Korea | 1 | Completed | Nov 27, 2025 | 50 |
| NCT04544319T2DM | 1 | UNKNOWN | Mar 2021 | 44 |
| NCT04255238Diabetes Mellitus, Type 2 | 3 | UNKNOWN | May 30, 2022 | 468 |
| NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | Aug 20, 2018 | 48 |
How it is read
Names in the registry
- “Dapagliflozin”, 90 entries
- “dapagliflozin”, 18 entries
- “Dapagliflozin 10 mg”, 6 entries
- “Dapagliflozin 10mg”, 5 entries
- “Dapagliflozin/metformin XR 10/1000mg”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 80 studies
- Renal Insufficiency, Chronic, 8 studies
- Heart Failure, 7 studies
- Diabetes Mellitus, 7 studies
- Diabetes Mellitus, Type 1, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.